688075 Assure Tech
- 33.52
- -1.06-3.07%
Assure Tech News
An Xu Biotech: Mainly drug testing and infectious disease testing products after COVID-19 | Direct performance report
① “After the demand for COVID-19 testing declined, the company's products are currently mainly drug testing products and infectious disease testing products.” ② In the future, An Xu Biotech will also need to address at least two aspects of single addiction, including excessive reliance on overseas income and a single dependency on product income.
Assure Tech (Hangzhou) (SHSE:688075) Could Be Struggling To Allocate Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employ
Express News | Anxu Biotech: Net profit of 70.198 million yuan in the first quarter increased 38.09% year-on-year
Anxu Biotech (688075.SH): Net profit in 2023 fell 95.34% year on year
Gelonghui, Feb. 28, 丨 An Xu Biotech (688075.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 508.2998 million yuan, a decrease of 91.76% over the same period of the previous year; realized net profit attributable to owners of the parent company of 141.7741 million yuan, a decrease of 95.34% over the same period last year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 52.44,800 yuan, a decrease of 98.24% from the same period last year.
Insiders Are the Top Stockholders in Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075), and the Recent 13% Drop Might Have Disappointed Them
Key Insights Insiders appear to have a vested interest in Assure Tech (Hangzhou)'s growth, as seen by their sizeable ownership The top 2 shareholders own 52% of the company Using data from company
Anxu Biotech (688075.SH): 2023 net profit pre-reduced by 94.98% to 95.82%
Gelonghui, January 30丨An Xu Biotech (688075.SH) announced its 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve net profit of 127.3982 million yuan to 152.887 million yuan in 2023. Compared with the same period last year (statutory disclosure data), it will decrease by 2891.754 million yuan to 2917.2751 million yuan, a year-on-year decrease of 94.98% to 95.82%. Net profit attributable to the owner of the parent company after deducting non-recurring profit and loss is expected to be 5,209.31 in 2023
[BT Financial Report Instantaneous Analysis] Anxu Biotech's 2023 Quarterly Report: Business Adjustments and Challenges Amidst Changes in Market Demand
Anxu Biotech (stock code: 688075) is a high-tech enterprise that is deeply involved in the field of POCT (instant diagnosis technology), focusing on R&D, production and sales of POCT reagents and instruments. Based on self-developed biomaterials, the company has built a diagnostic technology platform covering various fields such as drugs, infectious diseases, and chronic diseases, and has successfully sold its products to more than 150 countries around the world, becoming one of the Chinese suppliers that can compete with multinational in vitro diagnostic giants in the international market. Anxu Biotech adheres to the business principles of “fixing production by sales”, “determining procurement by production”, “moderate preparation”, and “quality is king”, and has formed
Anxu Biotech (688075.SH) will list 1,278,800 restricted shares for circulation on November 20
Anxu Biotech (688075.SH) announced that the number of strategically placed shares currently listed and distributed by the company is 127.0...
Anxu Biotech (688075.SH): Net profit for the first three quarters was 187 million yuan, a year-on-year decrease of 94.03%
On October 30, Gelonghui Biotech (688075.SH) disclosed its report for the third quarter of 2023. In the first three quarters, the company achieved revenue of 316 million yuan, a year-on-year decrease of 94.84%; net profit of 187 million yuan, a year-on-year decrease of 94.03%; non-net profit of 99.13 million yuan, a year-on-year decrease of 96.81%; and basic earnings per share of 1.47 yuan.
Recent 9.4% Pullback Would Hurt Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075) Insiders
Key Insights Insiders appear to have a vested interest in Assure Tech (Hangzhou)'s growth, as seen by their sizeable ownership The top 2 shareholders own 52% of the company Ownership research, com
An Xu Biotech: Some trust products are overdue
Glonghui, October 8 | An Xu Biotech announced on the evening of October 8, 2022, that on September 29, 2022, the company used its idle own capital of 100 million yuan to purchase Longsheng No. 1 trust products. Product period: September 29, 2022 - September 28, 2023. As of the disclosure date of the announcement, the company has not received the principal amount and investment income of the trust plan; the company has communicated with Zhongrong Trust several times on follow-up matters relating to the overdue payment of this trust plan. As of the disclosure date of the announcement, the company has not received an official document response from Zhongrong Trust. Subsequent companies will continue to urge China Finance Trust to pay the principal and investment income as soon as possible, and implement them in a timely manner
Declining Stock and Decent Financials: Is The Market Wrong About Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075)?
It is hard to get excited after looking at Assure Tech (Hangzhou)'s (SHSE:688075) recent performance, when its stock has declined 12% over the past three months. However, the company's fundamentals
An Xu Biotech (688075.SH) released first-half results, with net profit of 167 million yuan, down 94.20% year on year
An Xu Biotech (688075.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
The Recent CN¥583m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075)
Key Insights Insiders appear to have a vested interest in Assure Tech (Hangzhou)'s growth, as seen by their sizeable ownership 52% of the business is held by the top 2 shareholders Using data from
An Xu Biotech (688075.SH): 2022 Annual Equity Distribution of 10 to 4 Transfers of 50 Yuan
Gelonghui, June 20, 丨 An Xu Biotech (688075.SH) announced that the company plans to distribute a cash dividend of 5 yuan (tax included) per share in 2022, using the Capital Provident Fund to transfer 0.4 shares per share to all shareholders. The cash dividend will be distributed on June 29, 2023.
An Xu Biotech (688075.SH) plans to transfer 0.4 shares per share and distribute 5 yuan in dividends on June 29
According to the Zhitong Finance App, An Xu Biotech (688075.SH) announced that the company's annual equity distribution in 2022: it plans to distribute a cash dividend of 5 yuan per share (tax included) per share, using the Capital Provident Fund to transfer 0.4 shares per share to all shareholders. The cash dividend will be distributed on June 29, 2023.
An Xu Biology (688075.SH): The domestic pet in vitro diagnostic market is expected to continue to grow
Gelonghui June 7 丨 Some investors asked An Xu Biotech (688075.SH): What are the main aspects of pet testing products tested? How big is the market? An Xu Biotech replied: The medical segment in the pet industry is currently a blue ocean market, and the size of China's pet diagnosis market should not be underestimated. Currently, the animal in vitro diagnostic market is mainly concentrated in developed countries in Europe and the US. According to iResearch's “China Veterinary Diagnostic Products Industry Research Report”, the global veterinary in vitro diagnostic market (including livestock animals and pets) will be about 43.5 billion yuan in 2021, an increase of 10.5% over the previous year. China's pet diagnostic market is on the right track
An Xu Biotech (688075.SH): In the future, it will look for industries linked to the company's main business to lay out the biomedical health sector
Gelonghui, June 7 丨 Some investors asked An Xu Biotech (688075.SH): Does the company have plans to invest in mergers and acquisitions later? An Xu Biotech replied: In the future, it will look for industries related to the company's main business and lay out the biomedical health sector.
An Xu Biotech (688075.SH): The gross margin of drug testing products is 39%
Gelonghui, June 7 丨 Some investors asked An Xu Biotech (688075.SH): Which countries are the company's drug testing products mainly sold to? What is the sales model? What is the gross margin? An Xu Biotech replied: The company's drug testing products are mainly sold in European and American countries. There are government procurement tenders and dealer procurement forms. According to the company's 2022 annual report, the gross margin of drug testing products is 39%.
An Xu Biotech (688075.SH): The company's international market will mainly be sold to North America in 2022
Gelonghui, June 7 丨 Some investors asked An Xu Biotech (688075.SH): Which regions are the company's products mainly exported abroad? Will earnings be affected by foreign exchange fluctuations? An Xu Biotech replied: The company's international market in 2022 was mainly sold to North America, accounting for 74%; the second was Oceania, accounting for 17%; the third was Europe, accounting for 4.5%. Since the company's products are mainly sold overseas, the settlement currency is mainly the US dollar. To prevent the impact of large exchange rate fluctuations, the company has carried out forward foreign exchange settlement and foreign exchange derivatives business with banks to improve the efficiency of the use of foreign exchange funds and keep the company's performance stable. The industry
Analysis
Price Target
No Data
